Snipr Biome chose clinical debut in CRISPR-ready USA
Danish CRISPR company Snipr Biome is betting on the US following the FDA's thumbs-up to begin phase I clinical testing of its first drug candidate, says CEO Christian Grøndahl, who is in final talks with two US-based contractors for the trial.
by ULRICH QUISTGAARD, translated by daniel pedersen
Snipr Biome has great expectations for 2022 following the US Food and Drug Administration (FDA) approval of the company's application to initiate a phase I clinical trial with its first development candidate, which will be conducted in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Snipr Biome to send first candidate to clinic
For subscribers
Snipr Biome to collaborate with US cancer hospital
For subscribers
